Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...
April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study and sending ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the ...
The new report explained that the link between psoriasis and sleep disorders “is likely multifactorial, driven by ...
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical ...
At the recent American Academy of Dermatology (AAD) annual meeting, a presentation called "Psoriasis Beyond the Skin: Obesity ...
At week 16, 40 of 63 participants receiving ORKA-001 achieved PASI 100, corresponding to complete skin clearance.
Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results